Biodesix, Inc. is a data-driven commercial-stage molecular diagnostics enterprise specializing in the discovery, development, and commercialization of novel blood-based diagnostic tests and genomic assays. Utilizing proprietary machine learning platforms and advanced biotechnology techniques, the company focuses primarily on oncology, providing physicians with rapid diagnostic and prognostic tools for the early detection, personalized treatment selection, and monitoring of lung cancer and other complex diseases.